Correlation between Mitochondrial Reactive Oxygen and Severity of Atherosclerosis
Table 1
Body composition, plasma lipids and glucose levels, renal and hepatic function markers, systemic and mitochondrial redox parameters of LDL receptor knockout mice treated during 3 months with citrate and pravastatin.
Parameters
Control
Citrate
Pravastatin
Citrate + prava.
Body weight1
19.7 ± 0.2
17.7 ± 0.3
17.3 ± 0.4
18.2 ± 0.2
Carcass fat mass2
14.1 ± 0.7
15.6 ± 1.6
14.2 ± 1.0
13.1 ± 1.9
Carcass lean mass2
65.4 ± 0.9
64.5 ± 0.5
63.8 ± 0.6
64.9 ± 0.7
Visceral fat mass3
0.91 ± 0.08
0.93 ± 0.11
0.74 ± 0.07
0.84 ± 0.12
Liver mass3
4.68 ± 0.09
4.72 ± 0.08
4.63 ± 0.11
4.78 ± 0.04
Spleen mass3
0.27 ± 0.01
0.27 ± 0.01
0.25 ± 0.02
0.25 ± 0.00
Liver Cholesterol4
4.5 ± 0.6
5.1 ± 0.6
4.4 ± 0.6
5.9 ± 0.8
Liver Triglycerides4
79 ± 13.7
97 ± 17.8
69.3 ± 10.8
102.3 ± 15.6
Glucose5
85 ± 4.1
77 ± 4.1
85 ± 3.3
79 ± 4.2
Triglycerides5
103 ± 6.7
104 ± 6.6
110 ± 8.3
115 ± 8.8
Cholesterol5
234 ± 13.3
238 ± 8.4
238 ± 12.1
252 ± 9.1
Fatty acid6
0.80 ± 0.09
0.83 ± 0.06
0.75 ± 0.06
0.76 ± 0.03
LDLox antibodies7
0.34 ± 0.07
0.54 ± 0.08
0.42 ± 0.09
0.54 ± 0.07
TBARS6
258.5 ± 10.3
248.6 ± 7.8
234.5 ± 6.6
245.5 ± 15.2
ALT8
36.0 ± 2.1
48.7 ± 4.2
44.8 ± 4.5
38.7 ± 3.1
AST8
117.7 ± 11.4
138.1 ± 12.4
155.0 ± 27.9
130.0 ± 14.7
ALP8
158.1 ± 8
145.6 ± 15.7
173.1 ± 11.2
172.4 ± 7.7
Urea5
77.0 ± 2.4
84.7 ± 1.5
94.3 ± 5.4
81.8 ± 4.3
Creatinine5
0.12 ± 0.01
0.12 ± 0.01
0.12 ± 0.01
0.12 ± 0.01
mtROS production9
1.71 ± 0.19
2.02 ± 0.32
1.66 ± 0.08
1.83 ± 0.18
NADPH oxidation10
0.95 ± 0.13
0.80 ± 0.2
0.92 ± 0.21
0.73 ± 0.22
Atherosclerotic lesion area11
31.6 ± 8.8
43.8 ± 4.8
61.1 ± 12.8
116.8 ± 25.0
Data are mean ± SE ( = 8–10/group). Citrate (1.34 mM citric acid + 1.1 mM sodium citrate in the drinking water). Pravastatin (10 mg/Kg of body weight) in the drinking water (67 mg/L). 1g, 2% related to the dry carcass, 3% related to the body weight, 4mg/g of liver, 5mg/dL, 6μM, 7absorbance, 8U/L, 9nM DCF/mg protein min−1, 10M NADPH/mg protein min−1, 11μm2 × 103. .
